JPET Celsis microsomes equal better data

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sato, S.
Right arrow Articles by Miyata, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sato, S.
Right arrow Articles by Miyata, K.

Vol. 296, Issue 3, 697-703, March 2001

Pharmacological Effect of Tamsulosin in Relation to Dog Plasma and Tissue Concentrations: Prostatic and Urethral Retention Possibly Contributes to Uroselectivity of Tamsulosin

Shuichi Sato, Akiyoshi Ohtake, Hiroshi Matsushima1, Chikashi Saitoh, Shinji Usuda2 and Keiji Miyata

Pharmacology Laboratories, Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., Tsukuba, Japan

In the present study the pharmacokinetics and pharmacodynamics of tamsulosin were investigated in anesthetized male dogs. Hypogastric nerve stimulation elevated the intraurethral pressure (IUP), which was inhibited dose dependently by intraduodenal administration of tamsulosin (3-30 µg/kg). The inhibition peaked about 90 min after dosing and lasted up to 240 min. The basal mean blood pressure did not change significantly during the observation period. The plasma, prostatic, and urethral concentrations of tamsulosin were determined by the liquid chromatography-mass spectrometry/mass spectrometry method. The plasma concentration reached the maximal level within 30 min after dosing and gradually declined thereafter. The maximal total plasma concentration of tamsulosin (Cmax, t) and its unbound concentration (Cmax, u) correlated with the maximal effect on IUP response [r2 = 0.81 (p < 0.01, n = 15) and r2 = 0.84 (p < 0.01, n = 15), respectively]. Each individual unbound plasma concentration did not correlate, however, with its associated inhibition of IUP response (r2 = 0.04, n = 126). Although the plasma concentration of tamsulosin decreased nearly to the lower limit of quantitation 240 min after dosing, the prostatic and urethral concentrations remained high, i.e., 13 to 44 times greater than the plasma concentration. Our data demonstrate that the maximal inhibition by tamsulosin of IUP response is well correlated with the maximal plasma concentration in the early phase. The sustained effect of tamsulosin on IUP response that follows may be related to prostatic and urethral retention of tamsulosin.


1 Present address: Drug Metabolism Laboratories Institute for Drug Development Research, Yamanouchi Pharmaceutical Co., Ltd., 3-17-1, Hasune, Itabashi-Ku, Tokyo 174-8612, Japan.

2 Present address: Safety Research Laboratories, Institute for Drug Development Research, Yamanouchi Pharmaceutical Co., Ltd., 1-1-8, Azusawa, Itabashi-Ku, Tokyo 174-8511, Japan.


0022-3565/01/2963-0697$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
IOVSHome page
O. Parssinen, E. Leppanen, P. Keski-Rahkonen, T. Mauriala, B. Dugue, and M. Lehtonen
Influence of tamsulosin on the iris and its implications for cataract surgery.
Invest. Ophthalmol. Vis. Sci., September 1, 2006; 47(9): 3766 - 3771.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
A. A. Hancock, S. A. Buckner, M. E. Brune, T. A. Esbenshade, L. M. Ireland, S. Katwala, I. Milicic, M. D. Meyer, J. F. Kerwin Jr., and M. Williams
Preclinical Pharmacology of Fiduxosin, a Novel alpha 1-Adrenoceptor Antagonist with Uroselective Properties
J. Pharmacol. Exp. Ther., February 1, 2002; 300(2): 478 - 486.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics.